Tesla
TSLA
MicroStrategy
MSTR
MARA Holdings
MARA
Apple
AAPL
Microsoft
MSFT
US Stock MarketDetailed Quotes
LXEO Lexeo Therapeutics
- 6.880
- -0.250-3.51%
Close Dec 13 16:00 ET
- 6.880
- 0.0000.00%
Post 20:01 ET
227.49MMarket Cap-2.63P/E (TTM)
7.272High6.780Low166.35KVolume7.010Open7.130Pre Close1.15MTurnover0.89%Turnover RatioLossP/E (Static)33.07MShares22.33052wk High1.63P/B128.23MFloat Cap5.77052wk Low--Dividend TTM18.64MShs Float22.330Historical High--Div YieldTTM6.90%Amplitude5.770Historical Low6.936Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Lexeo Therapeutics Stock Forum
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints
Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling...
NEWS
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
No comment yet